Atrial Fibrillation (AF) and heart failure (HF) with reduced ejection fraction (HFrEF) frequently coexist, resulting in significant morbidity and mortality. Therapeutic options for patients with AF and HFrEF are limited due to few antiarrhythmic drug (AAD) choices and historically equivocal effects of procedural interventions on mortality. However, recent randomized trials examining catheter ablation (CA) in AF patients with HFrEF have shown a beneficial effect on arrhythmic burden and HF symptoms, as well as an improvement in mortality. This review focuses on the role of CA for AF patients with HFrEF.

中文翻译：

---

房颤导管消融在心力衰竭患者中的​​作用

心房颤动 (AF) 和射血分数降低 (HFrEF) 的心力衰竭 (HF) 经常共存，导致显着的发病率和死亡率。由于抗心律失常药物 (AAD) 选择很少，而且程序干预对死亡率的影响历来模棱两可，因此 AF 和 HFrEF 患者的治疗选择受到限制。然而，最近在 HFrEF 房颤患者中检查导管消融 (CA) 的随机试验表明，对心律失常负担和 HF 症状以及死亡率的改善都有益处。本综述重点关注 CA 在伴有 HFrEF 的 AF 患者中的作用。